Skip to main content
SpringerLink
Log in
Book cover

Neuroendocrine Tumors pp 267–281Cite as

Neuroendocrine Liver Metastases

  • Chapter
  • First Online:

  • 481 Accesses

Abstract

Hepatic metastases represent a fundamental consideration in the effective management of neuroendocrine neoplasms (NEN), given the high propensity of multiple forms of NEN to metastasise to the liver, and their stark effects on survival outcomes. The only curative modality at present is radical resection with microscopically clear margins. However, this is rarely available as most individuals harbour disease which is multifocal and therefore not technically amenable to such an approach. Furthermore, disease recurrence is a major limitation even in ‘R0’ resection. Alternative surgical strategies may include palliative resection or ‘debulking’ for patients with medically intractable symptoms or even liver transplantation. More recently, multimodal therapies have been evaluated, with results of combinations of surgical and non-surgical methods to attain disease control in the liver a novel paradigm. Here, we discuss the assessment of neuroendocrine liver metastases as pertains to the surgical armamentarium and clinical results attainable with such approaches.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Frilling A, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8–21.

    Article  PubMed  Google Scholar 

  2. Dasari A, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Pavel M, et al. ENETS consensus guidelines update for the Management of Distant Metastatic Disease of intestinal, pancreatic, bronchial Neuroendocrine Neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–85.

    Article  CAS  PubMed  Google Scholar 

  4. Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer. 2015;121:1172–86.

    Google Scholar 

  5. Clift AK, et al. Neuroendocrine neoplasms of the small bowel and pancreas. Neuroendocrinology. 2019. https://doi.org/10.1159/000503721.

  6. Elias D, et al. Hepatic metastases from neuroendocrine tumors with a ‘thin slice’ pathological examination: they are many more than you think. Ann Surg. 2010;251:307–10.

    Article  PubMed  Google Scholar 

  7. Frilling A, et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96:175–84.

    Article  CAS  PubMed  Google Scholar 

  8. Ronot M, et al. Morphological and functional imaging for detecting and assessing the resectability of neuroendocrine liver metastases. Neuroendocrinology. 2017. https://doi.org/10.1159/000479293.

  9. Mörk H, Ignee A, Schuessler G, Ott M, Dietrich CF. Analysis of neuroendocrine tumour metastases in the liver using contrast enhanced ultrasonography. Scand J Gastroenterol. 2007;42:652–62.

    Article  PubMed  Google Scholar 

  10. Ronot M, et al. Morphological and functional imaging for detecting and assessing the resectability of neuroendocrine liver metastases. Neuroendocrinology. 2018;106:74–88.

    Article  CAS  PubMed  Google Scholar 

  11. d’Assignies G, et al. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology. 2013;268:390–9.

    Article  PubMed  Google Scholar 

  12. Vilgrain V, et al. A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of colorectal liver metastases. Eur Radiol. 2016;26:4595–615.

    Google Scholar 

  13. Schraml C, et al. Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging. 2013;13:63–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ronot M, Clift AK, Vilgrain V, Frilling A. Functional imaging in liver tumours. J Hepatol. 2016;65:1017–30.

    Google Scholar 

  15. Breeman WAP, et al. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011;41:314–21.

    Article  PubMed  Google Scholar 

  16. Frilling A, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252:850–6.

    Article  PubMed  Google Scholar 

  17. Kayani I, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112:2447–55.

    Article  PubMed  Google Scholar 

  18. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978–85.

    Article  CAS  PubMed  Google Scholar 

  19. Christ E, et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol. 2013;1:115–22.

    Article  CAS  PubMed  Google Scholar 

  20. Pfeifer A, et al. 64Cu-DOTATATE PET for neuroendocrine Tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med. 2015;56:847–54.

    Article  CAS  PubMed  Google Scholar 

  21. Fairweather M, et al. Management of Neuroendocrine Tumor Liver Metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol. 2017;24:2319–25.

    Article  PubMed  Google Scholar 

  22. Maxwell JE, Sherman SK, O’Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy? Surgery. 2016;159:320–35.

    Article  PubMed  Google Scholar 

  23. Saxena A, et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery. 2011;149:209–20.

    Article  PubMed  Google Scholar 

  24. Scigliano S, et al. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocr Relat Cancer. 2009;16:977–90.

    Article  CAS  PubMed  Google Scholar 

  25. Gomez D, et al. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford). 2007;9:345–51.

    Article  CAS  Google Scholar 

  26. Elias D, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133:375–82.

    Article  PubMed  Google Scholar 

  27. Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol. 2012;21:e131–41.

    Article  PubMed  Google Scholar 

  28. Spolverato G, et al. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: an international multi-institutional analysis. J Surg Oncol. 2017;116:298–306.

    Article  CAS  PubMed  Google Scholar 

  29. Galleberg RB, et al. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. Eur J Surg Oncol. 2017;43:1682–9.

    Article  CAS  PubMed  Google Scholar 

  30. Bagante F, et al. Neuroendocrine liver metastasis: the chance to be cured after liver surgery. J Surg Oncol. 2017;115:687–95.

    Article  PubMed  Google Scholar 

  31. Manguso N, et al. Prognostic factors influencing survival in small bowel neuroendocrine tumor with liver metastases. J Surg Oncol. 2019;120:926–31.

    Article  PubMed  Google Scholar 

  32. Linecker M, et al. ALPPS in neuroendocrine liver metastases not amenable for conventional resection – lessons learned from an interim analysis of the international ALPPS registry. HPB. 2020;22:537–44.

    Article  PubMed  Google Scholar 

  33. Vouche M, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59:1029–36.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kianmanesh R, et al. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg. 2008;247:659–65.

    Article  PubMed  Google Scholar 

  35. Schnitzbauer AA, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255:405–14.

    Article  PubMed  Google Scholar 

  36. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–6.

    CAS  PubMed  Google Scholar 

  37. Sarmiento JM, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37.

    Article  PubMed  Google Scholar 

  38. Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163:218–25.

    Article  PubMed  Google Scholar 

  39. Fan ST, et al. Liver transplantation for neuroendocrine tumour liver metastases. HPB (Oxford). 2015;17:23–8.

    Article  Google Scholar 

  40. Gedaly R, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg. 2011;146:953–8.

    Article  PubMed  Google Scholar 

  41. Mangus RS, Tector AJ, Kubal CA, Fridell JA, Vianna RM. Multivisceral transplantation: expanding indications and improving outcomes. J Gastrointest Surg. 2013;17:179–86; discussion p. 186–7.

    Article  PubMed  Google Scholar 

  42. Olausson M, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl. 2007;13:327–33.

    Article  PubMed  Google Scholar 

  43. Mazzaferro V, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant. 2016;16:2892–902.

    Article  CAS  PubMed  Google Scholar 

  44. Bonaccorsi-Riani E, et al. Liver transplantation and neuroendocrine tumors: lessons from a single Centre experience and from the literature review. Transpl Int. 2010;23:668–78.

    Article  PubMed  Google Scholar 

  45. van Vilsteren FGI, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl. 2006;12:448–56.

    Article  PubMed  Google Scholar 

  46. Frilling A, et al. Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl. 2006;12:1089–96.

    Article  PubMed  Google Scholar 

  47. Moris D, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review. Surgery. 2017;162:525–36.

    Article  PubMed  Google Scholar 

  48. Nguyen NTT, Harring TR, Goss JA, O’Mahony CA. Neuroendocrine liver metastases and orthotopic liver transplantation: the US experience. Int J Hepatol. 2011;2011:742890.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Le Treut YP, et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013;257:807–15.

    Article  PubMed  Google Scholar 

  50. Kaemmerer D, et al. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol. 2009;15:5867–70.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Partelli S, et al. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery. 2017. https://doi.org/10.1016/j.surg.2017.11.007.

  52. Clift AK, et al. Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems. Endocr Connect. 2017;6:71–81.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Genç CG, et al. A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann Surg. 2018;267:1148–54.

    Article  PubMed  Google Scholar 

  54. Pusceddu S, et al. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocr Relat Cancer. 2018;25:607–18.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Fisher AT, et al. Management of ileal neuroendocrine tumors with liver metastases. J Gastrointest Surg. 2019:1–10. https://doi.org/10.1007/s11605-019-04309-7.

  56. Steyerberg EW, Harrell FE. Prediction models need appropriate internal, internal-external, and external validation. J Clin Epidemiol. 2016;69:245–7.

    Article  PubMed  Google Scholar 

  57. Öberg K, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. 2020;31:202–12.

    Article  PubMed  Google Scholar 

  58. Ćwikła JB, et al. Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. J Clin Endocrinol Metab. 2015;100:E1437–45.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery & Cancer, Imperial College London, London, UK

    Ashley Kieran Clift & Andrea Frilling

Authors
  1. Ashley Kieran Clift
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Frilling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Frilling .

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

    Jordan M. Cloyd

  2. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

    Timothy M. Pawlik

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Clift, A.K., Frilling, A. (2021). Neuroendocrine Liver Metastases. In: Cloyd, J.M., Pawlik, T.M. (eds) Neuroendocrine Tumors. Springer, Cham. https://doi.org/10.1007/978-3-030-62241-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62241-1_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62240-4

  • Online ISBN: 978-3-030-62241-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation